Article Text

other Versions

Download PDFPDF
Dexamethasone prevents visceral hyparalgesia but not colonic permeability increase induced by luminal protease-activated receptor-2 agonist in rats.
  1. Richard Roka (rori9{at}
  1. INRA, France
    1. Afifa AIt-Belgnaoui (afifa{at}
    1. INRA, France
      1. Christel Salvador-Cartier (cartier{at}
      1. INRA, France
        1. Raphael Garcia-villar (rgarciav{at}
        1. INRA, France
          1. Jean Fioramonti (jfioramo{at}
          1. INRA, France
            1. Helene Eutamene (heutamen{at}
            1. INRA, France
              1. Lionel Bueno (lbueno{at}
              1. INRA, France


                Background: Low-grade inflammation may play a role in the pathogenesis of IBS. Although corticosteroids are potent inhibitors of inflammatory processes, only one study with corticosteroids in patients with post-infectious IBS exists and suggests that prednisolone is not an effective treatment for IBS symptoms.

                Aim: The aim of this study was to evaluate if dexamethasone treatment prevents PAR-2 activation- induced visceral hyperalgesia and increased permeability in rats, and to determine if the effects involve colonic mast cells.

                Methods: Abdominal contractions provoked by rectal distension were recorded in rats equipped with intramuscular electrodes. Changes in visceral hypersensitivity provoked by intracolonic administration of PAR-2 activating peptide (SLIGRL), changes in colonic mucosal RMCP-II content, mast cell count and PAR-2 expression were measured after 4 day treatment with dexamethasone (1mg/day/rat ip) or its vehicle (water). Effect of mast cell stabilizer (doxantrazole, 1mg/kg ip, 2 hours before and 6 hours after intracolonic infusion of SLIGRL) on SLIGRL induced visceral hyperalgesia was also assessed. Effects of SLIGRL and a mast cell degranulator (C48/80) on permeability of colonic strips from vehicle or dexamethasone-treated rats were investigated in Ussing chambers.

                Results: Four days of dexamethasone as well as doxantrazole, diminished the SLIGRL-induced hyperalgesia for all volumes of distension. This effect of dexamethasone was accompanied by a reduced responsive of colonic permeability to C48/80and decreased RMCP-II content and mast cell number. Dexamethasone treatment did not influence colonic mucosal PAR-2 expression and permeability responsiveness to SLIGRL.

                Conclusions: Dexamethasone treatment improves PAR- 2 agonist-induced visceral hypersensitivity but does not prevent PAR-2 agonist-induced increase in colonic permeability in rats. This effect is coupled with a reduction of colonic mast cell number and RMCP-II contents.

                • PAR-2 activation
                • dexamethasone

                Statistics from

                Request Permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                Linked Articles

                • Digest
                  Robin Spiller Emad El-Omar